A Phase 1/2, Ascending Multiple-Dose Study to Evaluate the Safety, Efficacy and Pharmacokinetics of BMS-753493 in Subjects With Advanced Cancer (Schedule 2).
Phase of Trial: Phase I/II
Latest Information Update: 14 Oct 2015
At a glance
- Drugs BMS 753493 (Primary)
- Indications Advanced breast cancer; Ovarian cancer; Renal cancer
- Focus Adverse reactions; First in man
- 26 Jul 2010 Planned end date changed from 1 May 2010 to 1 Mar 2010 as reported by ClinicalTrials.gov.
- 01 Jul 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 01 Jul 2010 Planned end date changed from 1 Apr 2010 to 1 May 2010 as reported by ClinicalTrials.gov.